Table 5

Comparison between the AZISAST and AMAZES trials

Primary outcomes
Brusselle et al (AZISAST)30 18–75 years
GOLD step 4/5
>1000 µg fluticasone or equivalent
2 exacerbations requiring OCS in past 12/12
FeNO in normal limits
Azithromycin 250 mg thrice weekly26 weeks109
Exacerbation rate
Gibson et al (AMAZES)40 18 years or older
Diagnosis of asthma (post-bronchodilator reversibility >12%/airway hyper-responsiveness or PEFR variability >12%)
Partial loss of asthma control—ACQ≥0.75
Azithromycin 500 mg thrice weekly48 weeks420
Exacerbation rate
  • ACQ, Asthma Control Questionaire; GOLD, Global Initiative for Chronic Obstructive Lung Disease; OCS, Oral corticisteroids; PEFR, Peak Expiratory Flow Rate.